Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

Unlike traditional drug development, cell therapy logistics require extremely close, integrated relationships with contract research (CRO) and manufacturing (CDMO) organizations. Due to the direct line from patient to manufacturing and back, these partners function as critical extensions of the core team to ensure timeliness and safety.

Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

The build vs. outsource decision is strategic. Building in-house is justified when manufacturing is a core competitive advantage or the process itself is your key IP. Otherwise, outsourcing to a CDMO offers critical speed to clinic and preserves capital.

By partnering with Fujifilm Cellular Dynamics (FCDI), the company that developed its core technology, Kenai avoids a costly and risky tech transfer process. FCDI's existing facility can handle both clinical and future commercial scale-up, a significant operational and financial advantage.

To expand cell therapy globally, building facilities is insufficient. The key is forming alliances that transfer manufacturing processes, analytics knowledge, and provide local regulatory support to enable regions like Brazil to adopt these complex treatments and build self-sufficient ecosystems.

Scaling complex cell therapies follows a similar trajectory to monoclonal antibodies. The strategy involves establishing a global footprint with regional manufacturing facilities (e.g., US West, US East, Europe) to serve distinct geographic areas. This approach ensures manageable logistics and reliable delivery for personalized medicines, leveraging historical lessons.

A company's development approach is dictated by its business model. Startups use simple, low-cost methods for quick proof-of-concept data. Large pharma invests in robust, high-throughput systems to de-risk processes for regulatory demands. CDMOs must be flexible to serve both.

Companies often mistakenly expect their CDMO to fill strategic gaps. A CDMO's role is to execute the plan provided. Handing over an incomplete process is a 'wish,' not a tech transfer, and forces them to improvise in ways that may not align with your regulatory or commercial goals.